Guide to anticoagulant therapy: Heparin a statement for healthcare professionals from the American Heart Association

被引：396

作者：

Hirsh, J

Anand, SS

Halperin, JL

Fuster, V

机构：

来源：

CIRCULATION | 2001年 / 103卷 / 24期

关键词：

AHA Scientific Statement; anticoagulants; heparin;

D O I：

10.1161/01.CIR.103.24.2994

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2994 / 3018

页数：25

共 284 条

[51]

BRIANT L, 1989, THROMB HAEMOSTASIS, V61, P348

[52] ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].

BRILLEDWARDS, P ;

GINSBERG, JS ;

JOHNSTON, M ;

HIRSH, J .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109

[53] The inhibition of blood clotting: An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin [J].

Brinkhous, KM ;

Smith, HP ;

Warner, ED ;

Seegers, WH .

AMERICAN JOURNAL OF PHYSIOLOGY, 1939, 125 (04) :683-687

[54] LOW-MOLECULAR-WEIGHT HEPARIN REDUCES NEOINTIMAL PROLIFERATION AFTER CORONARY STENT IMPLANTATION IN HYPERCHOLESTEROLEMIC MINIPIGS [J].

BUCHWALD, AB ;

UNTERBERG, C ;

NEBENDAHL, K ;

GRONE, HJ ;

WIEGAND, V .

CIRCULATION, 1992, 86 (02) :531-537

[55] A COMPARISON OF THE ANTITHROMBOTIC AND HEMORRHAGIC EFFECTS OF LOW-MOLECULAR WEIGHT HEPARIN FRACTIONS - THE INFLUENCE OF THE METHOD OF PREPARATION [J].

CADE, JF ;

BUCHANAN, MR ;

BONEU, B ;

OCKELFORD, P ;

CARTER, CJ ;

CERSKUS, AL ;

HIRSH, J .

THROMBOSIS RESEARCH, 1984, 35 (06) :613-625

[56] Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty - The EMPAR study [J].

Cairns, JA ;

Gill, J ;

Morton, B ;

Roberts, R ;

Gent, M ;

Hirsh, J ;

Holder, D ;

Finnie, K ;

Marquis, JF ;

Naqvi, S ;

Cohen, E .

CIRCULATION, 1996, 94 (07) :1553-1560

[57] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[58]

CAMILLERI JF, 1988, ARCH MAL COEUR VAISS, V81, P1037

[59] DISAPPEARANCE OF CIRCULATING ANTI-XA ACTIVITY AFTER INTRAVENOUS-INJECTION OF STANDARD HEPARIN AND OF A LOW-MOLECULAR WEIGHT HEPARIN (CY-216) IN NORMAL AND NEPHRECTOMIZED RABBITS [J].

CARANOBE, C ;

BARRET, A ;

GABAIG, AM ;

DUPOUY, D ;

SIE, P ;

BONEU, B .

THROMBOSIS RESEARCH, 1985, 40 (01) :129-133

[60]

CARTER CJ, 1982, BLOOD, V59, P1239

← 1 2 3 4 5 6 7 8 9 10 →